Zacks Research Issues Negative Estimate for AGIO Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Research analysts at Zacks Research cut their Q2 2028 EPS estimates for Agios Pharmaceuticals in a research note issued on Friday, June 26th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings of ($1.21) per share for the quarter, down from their previous forecast of ($1.07). The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.28) per share.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.81) by $0.12. Agios Pharmaceuticals had a negative return on equity of 34.11% and a negative net margin of 639.84%.The firm had revenue of $20.75 million for the quarter, compared to the consensus estimate of $13.30 million. The company’s quarterly revenue was up 137.7% on a year-over-year basis.

Several other brokerages also recently commented on AGIO. JPMorgan Chase & Co. lowered their target price on Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating for the company in a research note on Thursday, June 11th. Bank of America cut their target price on shares of Agios Pharmaceuticals from $41.00 to $40.00 and set a “buy” rating on the stock in a research report on Friday, May 29th. Wall Street Zen upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, March 22nd. The Goldman Sachs Group boosted their price objective on Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 1st. Finally, Truist Financial dropped their target price on Agios Pharmaceuticals from $39.00 to $36.00 and set a “buy” rating for the company in a research report on Thursday, April 30th. Six equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $40.89.

Agios Pharmaceuticals Stock Down 0.1%

Shares of AGIO stock opened at $37.08 on Thursday. The business has a fifty day simple moving average of $29.75 and a 200 day simple moving average of $29.18. The company has a market cap of $2.21 billion, a P/E ratio of -5.11 and a beta of 0.54. Agios Pharmaceuticals has a twelve month low of $22.24 and a twelve month high of $46.00.

Hedge Funds Weigh In On Agios Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. T. Rowe Price Investment Management Inc. bought a new position in shares of Agios Pharmaceuticals during the 4th quarter worth about $25,000. Assetmark Inc. boosted its holdings in Agios Pharmaceuticals by 37.9% in the fourth quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 362 shares in the last quarter. NewEdge Advisors LLC acquired a new stake in Agios Pharmaceuticals in the first quarter valued at approximately $40,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Agios Pharmaceuticals during the fourth quarter valued at approximately $49,000. Finally, Quantbot Technologies LP bought a new stake in shares of Agios Pharmaceuticals during the third quarter valued at approximately $79,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.